[ad_1]
The UK laboratory AstraZeneca and the University of Oxford pointed this out this Monday in a joint statement the covid-19 vaccine they developed showed “70% effectiveness” in testing.
“The efficacy and safety of this vaccine confirm this it will be very effective against covid-19 and will have an immediate impact on this emergency public health, “AstraZeneca CEO Pascal Soriot said in a statement.
(Read also: The United States authorizes the use of the drug that Trump used against covid-19).
This vaccine, whose clinical trials are conducted, among other countries, in the UK and Brazil however, it is far less effective than the nearly 95% advertised for vaccines produced by its rivals Pfizer / BioNTech and Moderna.
But it uses more traditional technology than its two competitors, which makes it less expensive and easier to store, as it does not need to be stored at very low temperatures.
(Of your interest: Those who lead the race for covid-19 vaccines).
AstraZeneca estimated in the statement that its vaccine it is “highly effective” in preventing diseaseand noted that no participants developed severe coronavirus or had to be hospitalized during the tests.
(Read us from the App? Find the Oxford trill Here).
Preliminary results included studies involving more than 2,000 people, of whom 131 contracted the disease.
(Keep reading: The United States would begin vaccination against covid-19 in early December).
The efficacy ranged from 62% to 90% depending on the number of doses applied.
Specifically, the effectiveness rises to 90% in the case of a first sample of people who received half a dose and then a full dose one month later. Effectiveness drops to 62% in another group that received two doses in total one month apart.
The pharmaceutical group did not provide details to explain this difference.
In total, the large-scale Phase 3 clinical trials affect 60,000 people worldwide and are conducted in the United States, Japan, Russia, South Africa, Kenya and Latin America.
(Further: The danger of apartheid in the fight against vaccines).
Waiting for health approval
I congratulate “our brilliant scientists” and “all the volunteers in these trials”, said British Prime Minister Boris Johnson, celebrating the “fantastic results”.
But nevertheless, Johnson recalled that “further security checks still need to be carried out” before you can distribute it.
The UK, which has staked a lot on this project, has reserved 100 million doses.
These preliminary results included studies involving more than 2,000 people, of whom 131 contracted the disease.
(We recommend: Pfizer will apply today for authorization to market its covid-19 vaccine).
In total, the large-scale Phase 3 clinical trials affect 60,000 people worldwide and are conducted in the United States, Japan, Russia, South Africa, Kenya and Latin America.
The UK lab has announced that it will very quickly submit its results to authorities for first approval.
The effectiveness of these vaccines, developed in record time, is raising great hopes around the world as many countries are facing a second wave of coronavirus. And the restrictions and refinements in place weigh heavily on economies, with an explosion of unemployment and business failures.
If they get the green light quickly from their respective drug safety agencies, the first vaccines against covid-19 could begin to be distributed in December in the European Union and the United States.
(We suggest: The Ebola-like virus that scares Bolivia).
Thanks to its “simple supply chain”, the Oxford / AstraZeneca vaccine “will be accessible and available worldwide,” Soriot said.
“These results show that we have an effective vaccine that will save many lives.”said Professor Andrew Pollard of the University of Oxford.
The UK lab says it is making rapid progress in the planned production of 3 billion doses, which will be available in 2021.
AFP
.
[ad_2]
Source link
